Healios K.K (TYO:4593) has agreed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the clinical data package for conditional approval of MultiStem for Acute Respiratory Distress Syndrome, according to a Wednesday filing with the Tokyo Stock Exchange.
The approval will be based on Phase 2 trial results, with future Phase 3 data from the US as confirmatory support.
MultiStem is a regenerative medicine targeting ARDS, ischemic stroke, and trauma, and has received FDA Fast Track and RMAT designations.
Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。